Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

Donor type, in addition to transplantation in chronic phase and myeloablative conditioning, influence transplant survival for patients with advanced chronic myeloid leukemia in the era of tyrosine kinase inhibitors

Leukemia volume 31, pages 1654–1657 (2017)Cite this article

Subjects

To the editor:

Treatment of patients with chronic myeloid leukemia (CML) has changed dramatically over the years with the introduction of tyrosine kinase inhibitors (TKIs), now considered standard upfront therapy for this disease. Despite promising results, outcome of patients who present in advanced-phase or who progress while on TKI therapy is poor.1, 2 Allogeneic hematopoietic stem cell transplantation (AHSCT) remains the only potentially curative option for patients with advanced CML.3

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

References

  1. Jiang H, Xu LP, Liu DH, Liu KY, Chen SS, Jiang B et al. Allogeneic hematopoietic SCT in combination with tyrosine kinase inhibitor treatment compared with TKI treatment alone in CML blast crisis. Bone Marrow Transplant 2014; 49: 1146–1154.

    Article  CAS  Google Scholar 

  2. Palandri F, Castagnetti F, Alimena G, Testoni N, Breccia M, Luatti S et al. The long-term durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: the GIMEMA CML Working Party experience after a 7-year follow-up. Haematologica 2009; 94: 205–212.

    Article  CAS  Google Scholar 

  3. Khoury HJ, Kukreja M, Goldman JM, Wang T, Halter J, Arora M et al. Prognostic factors for outcomes in allogeneic transplantation for CML in the imatinib era: a CIBMTR analysis. Bone Marrow Transplant 2012; 47: 810–816.

    Article  CAS  Google Scholar 

  4. Ruggeri A, Labopin M, Ciceri F, Mohty M, Nagler A . Definition of GvHD-free, relapse-free survival for registry-based studies: an ALWP-EBMT analysis on patients with AML in remission. Bone Marrow Transplant 2016; 51: 610–611.

    Article  CAS  Google Scholar 

  5. Giralt S, Ballen K, Rizzo D, Bacigalupo A, Horowitz M, Pasquini M et al. Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research. Biol Blood Marrow Transplant 2009; 15: 367–369.

    Article  Google Scholar 

  6. Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 2009; 27: 6041–6051.

    Article  CAS  Google Scholar 

  7. Mahon FX, Rea D, Guilhot J, Guilhot F, Huguet F, Nicolini F et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 2010; 11: 1029–1035.

    Article  CAS  Google Scholar 

  8. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H et al WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. International Agency for Research on Cancer: Lyon, France, vol.2. 2008.

  9. Crawley C, Szydlo R, Lalancette M, Bacigalupo A, Lange A, Brune M et al. Outcomes of reduced-intensity transplantation for chronic myeloid leukemia: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT. Blood 2005; 106: 2969–2976.

    Article  CAS  Google Scholar 

  10. Kanate AS, Mussetti A, Kharfan-Dabaja MA, Ahn KW, DiGilio A, Beitinjaneh A et al. Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors. Blood 2016; 127: 938–947.

    Article  CAS  Google Scholar 

  11. Ciurea SO, Zhang MJ, Bacigalupo AA, Bashey A, Appelbaum FR, Aljitawi OS et al. Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia. Blood 2015; 126: 1033–1040.

    Article  CAS  Google Scholar 

  12. Kebriaei P, Detry MA, Giralt S, Carrasco-Yalan A, Anagnostopoulos A, Couriel D et al. Long-term follow-up of allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning for patients with chronic myeloid leukemia. Blood 2007; 110: 3456–3462.

    Article  CAS  Google Scholar 

  13. Blaise D, Furst S, Crocchiolo R, El-Cheikh J, Granata A, Harbi S et al. Haploidentical T cell-replete transplantation with post-transplantation cyclophosphamide for patients in or above the sixth decade of age compared with allogeneic hematopoietic stem cell transplantation from an human leukocyte antigen-matched related or unrelated donor. Biol Blood Marrow Transplant 2016; 22: 119–124.

    Article  Google Scholar 

  14. Di Stasi A, Milton DR, Poon LM, Hamdi A, Rondon G, Chen J et al. Similar transplantation outcomes for acute myeloid leukemia and myelodysplastic syndrome patients with haploidentical versus 10/10 human leukocyte antigen-matched unrelated and related donors. Biol Blood Marrow Transplant 2014; 20: 1975–1981.

    Article  Google Scholar 

  15. Raiola AM, Dominietto A, di Grazia C, Lamparelli T, Gualandi F, Ibatici A et al. Unmanipulated haploidentical transplants compared with other alternative donors and matched sibling grafts. Biol Blood Marrow Transplant 2014; 20: 1573–1579.

    Article  Google Scholar 

Download references

Author information

Author notes

  1. P Kongtim and K Adekola: These authors contributed equally to this work.

Authors and Affiliations

  1. Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA

    P Kongtim, K Adekola, R Ramlal, A Jimenez, J Chen, G Rondon, S Ahmed, P Kebriaei, O Betul, C M Hosing, U Popat, I Khouri, R E Champlin & S O Ciurea

  2. Department of Biostatistics, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA

    D R Milton

  3. Department of Leukemia, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA

    E Jabbour, J E Cortes & H M Kantarjian

Authors
  1. P Kongtim
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. K Adekola
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. D R Milton
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. R Ramlal
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A Jimenez
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. J Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. G Rondon
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. S Ahmed
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. P Kebriaei
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. O Betul
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. C M Hosing
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. U Popat
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. I Khouri
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. E Jabbour
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. J E Cortes
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. H M Kantarjian
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. R E Champlin
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. S O Ciurea
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S O Ciurea.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

Author contributions

P Kongtim collected data and wrote the manuscript; KA collected data, reviewed and approved the manuscript; DRM analyzed data, interpreted the results, reviewed and approved the manuscript; RR, AJ, JC, GR contributed with data collection, reviewed and approved the manuscript; SA, P Kebriaei, CMH, IK, EJ, OB, UP, JC, HMK, REC contributed with treatment of patients, reviewed and approved the manuscript; SOC contributed with study design, data collection and interpretation, and manuscript writing.

Supplementary Information accompanies this paper on the Leukemia website

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kongtim, P., Adekola, K., Milton, D. et al. Donor type, in addition to transplantation in chronic phase and myeloablative conditioning, influence transplant survival for patients with advanced chronic myeloid leukemia in the era of tyrosine kinase inhibitors. Leukemia 31, 1654–1657 (2017). https://doi.org/10.1038/leu.2017.118

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2017.118

This article is cited by

Search

Advanced search

Quick links